Lin, Lishi
Soesan, Marcel
van Balen, Dorieke E. M.
Beijnen, Jos H.
Huitema, Alwin D. R. http://orcid.org/0000-0003-1939-4639
Article History
Received: 1 March 2022
Accepted: 6 July 2022
First Online: 16 August 2022
Declarations
:
: The authors L. Lin, M. Soesan, D.E.M. van Balen, and A.D.R. Huitema declare that they have no relevant financial or non-financial interests to disclose. J.H. Beijnen is a part-time employee and (indirect) shareholder of Modra Pharmaceuticals BV. He is (partly) patent holder of oral taxane formulations which are clinically developed by Modra Pharmaceuticals BV (a spin-off company of The Netherlands Cancer Institute, not related to this manuscript).
: The conduct of this retrospective observational study was approved by the Investigational Review Board of the NKI-AvL.
: The need for written informed consent was waived.
: Not applicable.